ORPHA:404521
Spinal muscular atrophy with respiratory distress type 2
Also known as: Diaphragmatic spinal muscular atrophy type 2 · SMARD2 · Severe infantile axonal neuropathy with respiratory failure type 2 · X-linked spinal muscular atrophy with respiratory distress
Publications
20
30.9th percentile
Trials
0
Interventional, condition-specific
Researchers
143
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Spinal muscular atrophy with respiratory distress type 2 is a rare, genetic, motor neuron disease characterized by early respiratory failure associated with diaphragm paralysis, distal muscular weakness, joint contractures, and axial with preserved antigravity limb movements. overlaps considerably with SMARD type 1 but is differentiated by a mutation in a different gene.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018450
- UMLS:C4749434
Additional Mondo synonyms (2)
diaphragmatic spinal muscular atrophy type 2 · severe infantile axonal neuropathy with respiratory failure type 2
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
20 matched papers (13 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 166 for broader category spinal muscular atrophy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
20
20 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
20 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
13 in the last 10 years · high confidence · 30.9th percentile (publications denominator)
Phrase hits: 20 · MeSH hits: 0
Who's working on it?
143
Distinct author names in 20 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Sadowsky CL2 papers · 2023
International Center for Spinal Cord Injury/Kennedy Krieger Institute, Baltimore, Maryland.
Papers in Europe PMC - 02Abboud MR1 paper · 2017
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Papers in Europe PMC - 03Aggarwal D1 paper · 2021
Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 04Angurana SK1 paper · 2021
Department of Pediatrics, Pediatric Emergency and Intensive Care Unit, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 05Arkwright PD1 paper · 2017
Department of Paediatric Allergy and Immunology, University of Manchester, Royal Manchester Children's Hospital, Manchester, UK.
Papers in Europe PMC - 06Awano H1 paper · 2024
Organization for Research Initiative and Promotion, Research Initiative Center, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan.
Papers in Europe PMC - 07Bahrami E1 paper · 2017
Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Papers in Europe PMC - 08Bardhi L1 paper · 2023
Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy.
Papers in Europe PMC - 09Barik S1 paper · 2022
Epigenetic and Chromatin Biology Unit, Institute of Life Sciences, Bhubaneswar, India.
Papers in Europe PMC - 10Basu J1 paper · 2022
Epigenetic and Chromatin Biology Unit, Institute of Life Sciences, Bhubaneswar, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 166 trials are registered for spinal muscular atrophy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
166 interventional trials matched spinal muscular atrophy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: spinal muscular atrophy
166
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05866419·RECRUITING·Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy · Spine Deformity · Scoliosis·Matched via name phrase
- NCT07072676·ENROLLING BY INVITATION·The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Conditions: Inclusion Body Myositis · Myotonic Dystrophy 1 · Myotonic Dystrophy 2 · Facio-Scapulo-Humeral Dystrophy·Matched via name phrase
- NCT07488338·RECRUITING·HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT05861999·RECRUITING·A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Conditions: Muscular Atrophy, Spinal·Matched via name phrase
- NCT06322654·RECRUITING·A Head-to-head Study Comparing the Functional Value of Two Models of Robotically Assisted Rehabilitation in SMA (Spinal Muscular Atrophy) Patients
Conditions: SMA·Matched via name phrase
- NCT06363357·RECRUITING·The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder
Conditions: Muscular Dystrophy, Duchenne · Orthotic Devices · Upper Extremity · Neuromuscular Diseases (NMD)·Matched via name phrase
- NCT06321965·RECRUITING·Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy
Conditions: Spinal Muscular Atrophy·Matched via name phrase
- NCT07448610·NOT YET RECRUITING·ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Conditions: Spinal Muscular Atrophy·Matched via name phrase
- NCT05614531·ENROLLING BY INVITATION·Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
Conditions: Spinal Muscular Atrophy Type I·Matched via name phrase
- NCT07047144·RECRUITING·A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy · SMA · Spinal Muscular Atrophy Type 2 · Spinal Muscular Atrophy Type 3·Matched via name phrase
- NCT07332702·RECRUITING·Long Read Analysis in Spinal Muscular Atrophy - LOREASI
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT06977269·RECRUITING·Safety and Tolerability of Low Motoneuron Stimulation Via Transcranial Magnetic Stimulation in Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT07578454·RECRUITING·VRehab-SMA Phase 1.2
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT07287982·RECRUITING·A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Conditions: Spinal Muscular Atrophy (SMA)·Matched via name phrase
- NCT07444450·NOT YET RECRUITING·A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Conditions: Muscular Atrophy, Spinal·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Spinal muscular atrophy as a category (Group 3), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 3 — high-cost / lifelong therapy with careful selection
Up to ₹50 lakh per patient
Financial support at notified Centres of Excellence is the figure commonly cited in recent MoHFW/PIB statements. Many Group 3 patients also use the MoHFW voluntary-contribution / crowdfunding portal.
Eligibility and patient selection rules change. Verify with a CoE; the crowdfunding portal is a separate mechanism from CoE funding. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Spinal muscular atrophy with respiratory distress type 2" OR "Diaphragmatic spinal muscular atrophy type 2" OR "SMARD2" OR "Severe infantile axonal neuropathy with respiratory failure type 2" OR "X-linked spinal muscular atrophy with respiratory distress"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Spinal muscular atrophy with respiratory distress type 2" OR "Diaphragmatic spinal muscular atrophy type 2" OR "SMARD2" OR "Severe infantile axonal neuropathy with respiratory failure type 2" OR "X-linked spinal muscular atrophy with respiratory distress"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"spinal muscular atrophy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:36:32.213Z
